Cassava Sciences, Inc. (SAVA)
After hours:
| Previous close | 20.83 |
| Open | 20.93 |
| Bid | 20.76 x 1300 |
| Ask | 21.02 x 2200 |
| Day's range | 20.67 - 21.30 |
| 52-week range | 12.32 - 45.43 |
| Volume | |
| Avg. volume | 1,238,250 |
| Market cap | 877.221M |
| Beta (5Y monthly) | 0.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.29 |
| Earnings date | 26 Feb 2024 - 01 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 13 Dec 2012 |
| 1y target est | 99.50 |
Simply Wall St.Cassava Sciences, Inc. (NASDAQ:SAVA): Is Breakeven Near?
With the business potentially at an important milestone, we thought we'd take a closer look at Cassava Sciences, Inc.'s...
GlobeNewswireCassava Sciences Reports Third Quarter 2023 Financial and Operating Results
Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected approximately year-end 2024; top-line results for 76-week Phase 3 trial expected approximately mid-year 2025.MRI safety data suggests simufilam is not associated with ARIA.$142.4 Million in cash and cash equivalents at September 30, 2023. AUSTIN, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc
- GlobeNewswire
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia.Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end 2024.Top-line results for on-going, 76-week Phase 3 trial expected approximately mid-year 2025. AUSTIN, Texas, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pair of Phase 3 trials to evaluate
